JP6241890B2 - 血管組織およびその作製方法 - Google Patents
血管組織およびその作製方法 Download PDFInfo
- Publication number
- JP6241890B2 JP6241890B2 JP2014531532A JP2014531532A JP6241890B2 JP 6241890 B2 JP6241890 B2 JP 6241890B2 JP 2014531532 A JP2014531532 A JP 2014531532A JP 2014531532 A JP2014531532 A JP 2014531532A JP 6241890 B2 JP6241890 B2 JP 6241890B2
- Authority
- JP
- Japan
- Prior art keywords
- vascular tissue
- sodium alginate
- cells
- channel structure
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000002792 vascular Effects 0.000 title claims description 115
- 238000004519 manufacturing process Methods 0.000 title claims description 31
- 210000001519 tissue Anatomy 0.000 claims description 147
- 210000004027 cell Anatomy 0.000 claims description 146
- 239000000017 hydrogel Substances 0.000 claims description 125
- 235000010443 alginic acid Nutrition 0.000 claims description 112
- 229920000615 alginic acid Polymers 0.000 claims description 112
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 86
- 229940072056 alginate Drugs 0.000 claims description 86
- 239000007864 aqueous solution Substances 0.000 claims description 81
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 79
- 239000000661 sodium alginate Substances 0.000 claims description 79
- 235000010413 sodium alginate Nutrition 0.000 claims description 79
- 229940005550 sodium alginate Drugs 0.000 claims description 79
- 239000000463 material Substances 0.000 claims description 59
- 150000001768 cations Chemical class 0.000 claims description 44
- 239000000243 solution Substances 0.000 claims description 42
- 229910052751 metal Inorganic materials 0.000 claims description 36
- 239000002184 metal Substances 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 35
- 229960001126 alginic acid Drugs 0.000 claims description 26
- 239000000783 alginic acid Substances 0.000 claims description 26
- 150000004781 alginic acids Chemical class 0.000 claims description 26
- 229920000936 Agarose Polymers 0.000 claims description 17
- 210000004204 blood vessel Anatomy 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 108010035532 Collagen Proteins 0.000 claims description 9
- 102000008186 Collagen Human genes 0.000 claims description 9
- 229920001436 collagen Polymers 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 8
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 6
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 6
- -1 polydimethylsiloxane Polymers 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 6
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 5
- 229910001424 calcium ion Inorganic materials 0.000 claims description 5
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 229910001422 barium ion Inorganic materials 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 229910001427 strontium ion Inorganic materials 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920002873 Polyethylenimine Polymers 0.000 claims description 3
- 239000012062 aqueous buffer Substances 0.000 claims description 3
- 230000004956 cell adhesive effect Effects 0.000 claims description 3
- 125000004386 diacrylate group Chemical group 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 108010082117 matrigel Proteins 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- PWYYWQHXAPXYMF-UHFFFAOYSA-N strontium(2+) Chemical compound [Sr+2] PWYYWQHXAPXYMF-UHFFFAOYSA-N 0.000 claims description 3
- 239000006285 cell suspension Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000010410 layer Substances 0.000 description 100
- 239000007788 liquid Substances 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 238000001000 micrograph Methods 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 9
- 239000001110 calcium chloride Substances 0.000 description 9
- 229910001628 calcium chloride Inorganic materials 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 239000002356 single layer Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000002073 fluorescence micrograph Methods 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 239000011543 agarose gel Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000000465 moulding Methods 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 6
- 239000002473 artificial blood Substances 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 238000001879 gelation Methods 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012533 medium component Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002861 polymer material Substances 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000003841 chloride salts Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000007641 inkjet printing Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 230000008560 physiological behavior Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 238000004804 winding Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920001486 SU-8 photoresist Polymers 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 108010045649 agarase Proteins 0.000 description 1
- 239000012237 artificial material Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000008883 metastatic behaviour Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
- C12N5/0691—Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/74—Alginate
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Prostheses (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Materials For Medical Uses (AREA)
Description
Claims (22)
- 多価の金属カチオン又は多価の金属カチオンを含む無機塩を含む素材によって構成される流路構造に対し、
細胞を懸濁させた第1のアルギン酸ナトリウム水溶液を導入し、前記流路構造の内壁に細胞を含む第1のアルギン酸ハイドロゲル層を形成した後、
前記流路構造内に残存するゲル化していない前記第1のアルギン酸ナトリウム水溶液を除去する、血管組織の作製方法。 - ゲル化していない前記第1のアルギン酸ナトリウム水溶液を除去した後、
前記流路構造に、細胞を懸濁させた第2のアルギン酸ナトリウム水溶液を導入し、前記第1のアルギン酸ハイドロゲル層の内壁に、細胞を含む第2のアルギン酸ハイドロゲル層を形成した後、
前記流路構造内に残存するゲル化していない前記第2のアルギン酸ナトリウム水溶液を除去する、請求項1に記載の血管組織の作製方法。 - 前記第1のアルギン酸ナトリウム水溶液を除去した後、あるいは前記第2のアルギン酸ナトリウム水溶液を除去した後に、前記流路構造に対し、細胞懸濁液を導入する、請求項1乃至2のいずれか1項に記載の血管組織の作製方法。
- 前記第1のアルギン酸ナトリウム水溶液を導入する直前に、前記流路構造に対し、多価のカチオンを含まない、あるいは多価のカチオン濃度が十分に低い、バッファー水溶液を導入する、請求項1乃至3のいずれか1項に記載の血管組織の作製方法。
- 前記バッファー水溶液は、クエン酸及びエチレンジアミン四酢酸の少なくともいずれかを含む、請求項4に記載の血管組織の作製方法。
- 前記第1のアルギン酸ナトリウム水溶液を除去した後、又は、前記第2のアルギン酸ナトリウム水溶液を除去した後に、前記流路構造に対し、多価の金属カチオンを含む水溶液を導入する、請求項1乃至5のいずれか1項に記載の血管組織の作製方法。
- 前記流路構造を構成する素材に対し、物理的操作及び化学的処理の少なくともいずれかを施すことにより、前記流路構造の内壁に形成された前記細胞を含むアルギン酸ハイドロゲル層を前記流路構造から分離し回収する、請求項1乃至6のいずれか1項に記載の血管組織の作製方法。
- 前記流路構造を構成する素材は、少なくとも部分的にハイドロゲル材料である、請求項1乃至7のいずれか1項に記載の血管組織の作製方法。
- 前記ハイドロゲル材料は、アルギン酸、アガロース、ゼラチン、コラーゲン、及び、ポリエチレングリコールジアクリレートの少なくともいずれかを含んで構成されている、請求項8に記載の血管組織の作製方法。
- 前記流路構造を構成する素材は、少なくとも部分的にポリジメチルシロキサンである、請求項1乃至7のいずれか1項に記載の血管組織の作製方法。
- 前記多価の金属カチオンとは、カルシウムイオン、ストロンチウムイオン、及び、バリウムイオンの少なくともいずれかである請求項1乃至10のいずれか1項に記載の血管組織の作製方法。
- 前記第1のアルギン酸ナトリウム水溶液および前記第2のアルギン酸ナトリウム水溶液に含まれるアルギン酸ナトリウムの濃度は、それぞれ0.1%(w/v)以上10%(w/v)以下である、請求項1乃至11のいずれか1項に記載の血管組織の作製方法。
- 前記流路構造は、その内壁面が予めポリカチオンによって表面処理されている、請求項1乃至12のいずれか1項に記載の血管組織の作製方法。
- 前記ポリカチオンは、ポリ−L−リジン、キトサン、及び、ポリエチレンイミンの少なくともいずれかを含む、請求項13に記載の血管組織の作製方法。
- 前記第1のアルギン酸ナトリウム水溶液および前記第2のアルギン酸ナトリウム水溶液のうちの少なくとも一方には、コラーゲン及びマトリゲルの少なくともいずれかが添加されている、請求項1乃至14のいずれか1項に記載の血管組織の作製方法。
- 前記第1のアルギン酸ナトリウム水溶液および前記第2のアルギン酸ナトリウム水溶液のうちの少なくとも一方には、細胞接着性アルギン酸ナトリウムが添加されている、請求項1乃至15のいずれか1項に記載の血管組織の作製方法。
- 前記細胞とは、哺乳動物由来の細胞である、請求項1乃至16のいずれか1項に記載の血管組織の作製方法。
- 前記細胞とは、血管平滑筋細胞、血管内皮細胞、及び血管上皮細胞の少なくともいずれかを含む、請求項1乃至17のいずれか1項に記載の血管組織の作製方法。
- 前記第1のアルギン酸ナトリウム水溶液および前記第2のアルギン酸ナトリウム水溶液に含まれる細胞の密度は、それぞれ1mL当たり1000万個以上である、請求項1乃至18のいずれか1項に記載の血管組織の作製方法。
- 前記第1のアルギン酸ナトリウム水溶液および前記第2のアルギン酸ナトリウム水溶液に、それぞれ含まれる細胞は、その種類、密度、及び、混合比率のうちの少なくともいずれか1つが異なる、請求項2乃至19のいずれか1項に記載の血管組織の作製方法。
- 前記第1のアルギン酸ハイドロゲル層および前記第2のアルギン酸ハイドロゲル層は、その厚みがそれぞれ10マイクロメートル以上である、請求項1乃至20のいずれか1項に記載の血管組織の作製方法。
- 前記血管組織は、少なくとも部分的に多層状構造、中空構造、および分岐構造を有する、請求項1乃至21のいずれか1項に記載の血管組織の作製方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012181261 | 2012-08-18 | ||
JP2012181261 | 2012-08-18 | ||
PCT/JP2013/066993 WO2014030418A1 (ja) | 2012-08-18 | 2013-06-20 | 血管組織およびその作製方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2014030418A1 JPWO2014030418A1 (ja) | 2016-07-28 |
JP6241890B2 true JP6241890B2 (ja) | 2017-12-06 |
Family
ID=50149736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014531532A Expired - Fee Related JP6241890B2 (ja) | 2012-08-18 | 2013-06-20 | 血管組織およびその作製方法 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP6241890B2 (ja) |
WO (1) | WO2014030418A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210137842A (ko) * | 2020-05-11 | 2021-11-18 | 재단법인 아산사회복지재단 | 인공 혈관을 포함한 생체 구조물 형성용 멤브레인, 상기 멤브레인을 포함하는 인공 생체 구조물 및 이들의 제조방법 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3418375B1 (en) * | 2016-02-16 | 2024-03-20 | Osaka University | Method for producing three-dimensional tissue having vascular system structure, and three-dimensional tissue comprising gel having vascular system structure |
CN107320780B (zh) * | 2017-06-27 | 2020-04-28 | 上普博源(北京)生物科技有限公司 | 一种中空管结构的多层水凝胶及其制备方法与应用 |
JP7090868B2 (ja) * | 2017-10-19 | 2022-06-27 | 国立大学法人 東京大学 | 接着剤及びその使用 |
JP7511565B2 (ja) * | 2018-09-14 | 2024-07-05 | バイオセイピエン インコーポレイテッド | 組織工学における使用のための生体脈管 |
WO2021080516A1 (en) * | 2019-10-23 | 2021-04-29 | Singapore University Of Technology And Design | Method of forming a vasculature structure and a vasculature structure thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2859381B1 (fr) * | 2003-09-05 | 2008-07-25 | Centre Nat Rech Scient | Utilisaton de cellules issues du tissu adipeux pour induire la formation d'un reseau vasculaire fonctionnel |
US8003388B2 (en) * | 2006-03-24 | 2011-08-23 | Nortis, Inc. | Method for creating perfusable microvessel systems |
JP5674442B2 (ja) * | 2010-12-08 | 2015-02-25 | 国立大学法人 東京大学 | 血管様構造物を含む三次元細胞培養物 |
JP5945802B2 (ja) * | 2011-05-31 | 2016-07-05 | 国立大学法人 千葉大学 | 複合型肝細胞組織体およびその作製方法 |
-
2013
- 2013-06-20 WO PCT/JP2013/066993 patent/WO2014030418A1/ja active Application Filing
- 2013-06-20 JP JP2014531532A patent/JP6241890B2/ja not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210137842A (ko) * | 2020-05-11 | 2021-11-18 | 재단법인 아산사회복지재단 | 인공 혈관을 포함한 생체 구조물 형성용 멤브레인, 상기 멤브레인을 포함하는 인공 생체 구조물 및 이들의 제조방법 |
KR102473438B1 (ko) | 2020-05-11 | 2022-12-02 | 재단법인 아산사회복지재단 | 인공 혈관을 포함한 생체 구조물 형성용 멤브레인, 상기 멤브레인을 포함하는 인공 생체 구조물 및 이들의 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
WO2014030418A1 (ja) | 2014-02-27 |
JPWO2014030418A1 (ja) | 2016-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jang et al. | Biomaterials-based 3D cell printing for next-generation therapeutics and diagnostics | |
JP6241890B2 (ja) | 血管組織およびその作製方法 | |
Leberfinger et al. | Bioprinting functional tissues | |
Onoe et al. | Cell-laden microfibers for bottom-up tissue engineering | |
Hoch et al. | Bioprinting of artificial blood vessels: current approaches towards a demanding goal | |
JP6712220B2 (ja) | 包埋された脈管構造を有する組織構成物をプリントする方法 | |
JP5985570B2 (ja) | 自己集合性多細胞体、および前記多細胞体を用いて3次元の生物構造体を作製する方法 | |
EP2617811B1 (en) | Method for manufacturing multilayered cell sheet, multilayered cell sheet having vascular network obtained thereby, method of use thereof | |
JP5524824B2 (ja) | 改良されたバイオリアクタ表面 | |
US9217129B2 (en) | Oscillating cell culture bioreactor | |
JP5945802B2 (ja) | 複合型肝細胞組織体およびその作製方法 | |
CN108149342B (zh) | 基于微流控技术的复合空腔微纤维的制备方法 | |
Li et al. | A versatile method for fabricating tissue engineering scaffolds with a three-dimensional channel for prevasculature networks | |
JP6628416B2 (ja) | 細胞培養方法 | |
US20170130184A1 (en) | Hollow microfiber | |
He et al. | Layer-by-layer micromolding of natural biopolymer scaffolds with intrinsic microfluidic networks | |
Li et al. | Rapid fabrication of ready-to-use gelatin scaffolds with prevascular networks using alginate hollow fibers as sacrificial templates | |
JP2021003527A (ja) | 生体親和性多孔質膜、バイオカプセルデバイスおよび生体親和性多孔質膜の製造方法 | |
Li et al. | Advances of 3D printing in vascularized organ construction | |
Zhou et al. | Biofabrication strategies with single-cell resolution: a review | |
Cross-Najafi et al. | The long road to develop custom-built livers: current status of 3D liver bioprinting | |
Thangadurai et al. | Emerging perspectives on 3D printed bioreactors for clinical translation of engineered and bioprinted tissue constructs | |
JP6452304B2 (ja) | 細胞シート培養基材、細胞シート培養基材複合物、及び細胞シート/培養基材複合の製造方法 | |
Zhang | 3D bioprinting of vasculature network for tissue engineering | |
Lu et al. | Biofabrication with microbial cellulose: from bioadaptive designs to living materials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160616 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170412 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170414 |
|
RD05 | Notification of revocation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7425 Effective date: 20170913 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171024 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171101 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6241890 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |